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Tumor Antigen Recognition by 
Cytolytic T Lymphocytes
CD8+ cytolytic T lymphocytes (CTLs) 
are the primary effector cells of the 
adaptive immune system and have a 
major role in protecting us from a vast 
array of diseases including cancer. 
CTLs speciﬁ  cally recognize and lyse 
targets through the interaction of T 
cell receptors (TCRs) on the surface 
of the T lymphocyte with protein 
fragments (peptides) presented on the 
surface of target cells, in association 
with major histocompatibility complex 
(MHC) class I molecules. When a 
particular CTL interacts with a target 
cell, it rapidly divides to form a clonal 
population of T cells with the identical 
TCR. 
Townsend and colleagues ﬁ  rst 
elucidated the molecular basis of 
target cell recognition by CTLs in 1985 
[1]. They showed that antigens are 
processed inside the target cell into 
nine- or ten-amino-acid-long peptides, 
which are then presented at the 
surface in association with MHC class 
I molecules. This discovery suggested 
the possibility of using short synthetic 
peptides mimicking naturally processed 
antigens as immunotherapeutic drugs 
and vaccines. Short synthetic peptides 
are ideal for drug development because 
of the relatively low cost of production, 
easy storage, and high safety. However, 
not all peptides and MHC alleles work 
well together to stimulate CTLs. So 
for clinical use, either patients would 
have to be selected for treatment based 
on their MHC I type or it would be 
necessary to make multiple peptides 
to cover the majority of MHC class I 
alleles in a given population.
Furthermore, before Boon and 
colleagues cloned the ﬁ  rst antigen 
recognized by tumor-reactive CTLs 
in 1991 [2], it was not clear which 
antigens were recognized by tumor-
reactive CTLs in humans; so, it was not 
possible to rationally design cancer 
vaccines. Now, however, a long list of 
more or less tumor-speciﬁ  c antigens 
has been generated [3]. Most of the 
peptides identiﬁ  ed so far are either 
normal self proteins aberrantly 
expressed in cancer but not in most 
other adult normal tissues or tissue-
speciﬁ  c antigens also expressed 
in certain types of cancer. Some 
patients show a spontaneous CD8+ T 
cell response (occasionally at high 
levels) that is speciﬁ  c for several of 
these antigens. The development of 
such responses, however, requires a 
large tumor load, occurs late in the 
disease, and probably does not cause 
the efﬁ  cient destruction of the tumor 
cells [4]. Thus, a central objective in 
cancer immunotherapy is to efﬁ  ciently 
produce tumor-reactive CTLs at an 
earlier phase of the disease.
Heteroclitic Tumor Antigen 
Peptides
Unfortunately, some synthetic peptides, 
including some corresponding to 
immunodominant epitopes (those 
which cause the biggest part of the 
immune response) from tumor 
antigens, only seem to bind MHC class 
I molecules with medium to low afﬁ  nity 
and/or are recognized by speciﬁ  c T 
cells with relatively low avidity. These 
characteristics are the likely cause of 
the poor immune reaction generated 
by these peptides [5]. One strategy 
to improve the immune reaction is 
to make what are called heteroclitic 
antigen variants. By improving either 
peptide binding to MHC, recognition 
by TCRs, or both, these variants have 
increased peptide antigenicity and 
immunogenicity. 
Solinger and colleagues were the ﬁ  rst 
to describe antigen variants producing 
T cell responses that were stronger 
than those elicited by the parental 
sequences [6]. Some heteroclitic 
tumor antigen peptides that showed 
highly improved antigenicity and 
immunogenicity in preclinical studies, 
and which also cross-reacted well with 
CTLs generated against the parental 
sequence, were tested in clinical trials. 
The peptides selected for trials mostly 
contained substitutions of anchoring 
amino acids that were designed to 
increase peptide binding to the MHC 
molecule while minimally changing the 
shape of the epitope [7,8]. 
In a study by Lee and colleagues in 
this issue of PLoS Medicine [9], despite 
the careful study design, vaccination 
with these peptides resulted in the 
recruitment of T cells that bound 
antigens less efﬁ  ciently and had lower 
tumor reactivity than those from the 
endogenous response to the tumor. 
The authors propose that the cause 
for the decreased afﬁ  nity of vaccine-
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elicited CTLs could be the high 
antigen density of these synthetic 
peptides on antigen-presenting cells. 
An alternative explanation, however, 
is that the synthetic peptides used for 
vaccination simply fail to faithfully 
mimic the naturally processed antigens 
(Figure 1). The use of peptides that 
differ from those resulting from natural 
intracellular processing has previously 
given rise to similar problems [10,11]. 
In any case, the enormous diversity in 
the normal TCR repertoire provides a 
molecular explanation of the observed 
phenomenon. These results emphasize 
how difﬁ  cult it is to translate ﬁ  ndings, 
such as the spectacular results obtained 
by the vaccination of TCR transgenic 
mice with heteroclitic peptides [12], 
into an application for normal animals 
and humans.
Conclusion
It is increasingly clear that even the 
smallest alteration in the structure 
of the MHC peptide complex can 
result in signiﬁ  cant changes in which 
TCRs are selected after vaccination. 
Thus, manipulating the immune T 
cell repertoire in vivo through the 
use of heteroclitic tumor antigen 
peptide variants could be harder 
than anticipated. As the ﬁ  eld moves 
rapidly towards the use of new vaccine 
adjuvants with high immunogenic 
potential [13], reassessment of the 
immunogenicity of natural sequences 
could be worthwhile in some cases. In 
addition, the careful analysis of antigen-
speciﬁ  c T cell clones, such as that 
reported here by Lee and colleagues, 
will be crucial to ascertain the quality of 
the elicited immune response.  
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Figure 1. Synthetic Peptides Used for Vaccination May Fail to Faithfully Mimic the Naturally 
Processed Antigens
The TCR repertoire speciﬁ  c for the natural tumor antigen (N) contains a group of CD8+ 
T cells that recognize N with high functional avidity and display high tumor reactivity 
(TCR-A, focused). TCR-A is stimulated by the natural ligand and expands during 
spontaneous responses to the tumor in some patients with antigen-expressing tumors. A 
larger group of CD8+ T cells able to recognize N also exists in the naïve T cell repertoire 
(TCR-B). TCR-B recognizes N with decreased avidity and shows low to undetectable 
tumor reactivity (unfocused). Heteroclitic peptides (H) are analogs of N that contain 
modiﬁ  cations that increase their immunogenicity. They are selected on the basis of their 
increased recognition by T cells from the TCR-A group. When used as immunogens, 
they elicit a group of CD8+ T cells speciﬁ  c for H (TCR-C). The reactivity of TCR-C will 
be variable and will depend on the extent of overlapping between the TCR-A, -B, and -C 
groups. In Lee and colleagues’ study [9], most of the elicited CD8+ T cells belong to the 
TCR-B group (unfocused), suggesting a large overlap between TCR-C and TCR-B and a 
more limited overlap of TCR-C with TCR-A. This phenomenon can be explained by the 
structural difference between N and H. Other factors that may differ between natural 
and peptide-induced immune responses, including the density of the peptide on antigen-
presenting cells and the mode of presentation (i.e., the nature of antigen-presenting 
cells), could also contribute to the outcome.